It is a pleasure to report that the Basilea Pharmaceutica AG (VTX:BSLN) is up 43% in the last quarter. But that...

(Bloomberg) -- JPMorgan Chase & Co. strategists are betting that the surge in demand for Treasuries thanks to fears about the deadly coronavirus will prove short-lived, sticking with a call to sell longer-dated bonds.Among the Wall Street bank’s other takeaways from their latest market-outlook reports: the outbreak of the disease is a “clear negative” for emerging Asian currencies, while for stocks it could be a buying opportunity if historical parallels hold.“This is the latest risk of a series that have driven U.S. Treasury yields far below what fundamentals indicate,” strategists including Matthew Jozoff wrote in a note Friday. “We don’t intend to be dismissive of the coronavirus, as it is a serious concern both in human and economic turns,” they wrote, while flagging that JPMorgan analysis notes a trend toward reduced mortality in health epidemics over time.Geopolitical tensions stemming from Iran spurred a rally in Treasuries earlier this month, before the coronavirus emerged as a new threat to global economic growth. The bond bid extended on Monday, with 10-year U.S. yields sliding as low as 1.62%, the lowest since October.That latest leg down came after JPMorgan strategists had calculated that yields were almost 30 basis points “too low” compared with expectations for growth, inflation and Federal Reserve policy decisions, along with gauges of investor positioning and the share of negative-yielding debt in developed markets.“Ten-year Treasuries have not been this dislocated on this basis since a brief period in the spring of 2015,” JPMorgan calculated. “We remain short 30-year U.S. Treasuries.”‘Buying Opportunities’Turning to stocks, JPMorgan’s equity strategists flagged that the health-scare could lead to more near-term declines, while concluding that “past pandemics episodes didn’t lead to sustained selling, they tended to ultimately be buying opportunities.”On the currency side, JPMorgan shifted its emerging Asia position to neutral, thanks to closing its overweight recommendation on Malaysia’s ringgit, which on Friday snapped a four-week winning streak.“Such outbreaks can subside as quickly as they have emerged,” JPMorgan currency strategists led by Paul Meggyesi wrote. “However, previous episodes show that risk appetite can be disrupted for at least a number of weeks, particularly from an FX standpoint.”(Adds comments on stocks and currencies starting in second paragraph.)To contact the reporter on this story: Christopher Anstey in Tokyo at canstey@bloomberg.netTo contact the editors responsible for this story: Chris Nagi at chrisnagi@bloomberg.net, Cormac Mullen, Ravil ShirodkarFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). To keep it practical, we'll...

Endomines AB (publ) (STO:ENDO) shareholders should be happy to see the share price up 16% in the last month. But that...

Arix Bioscience plc ("Arix", LSE: ARIX) a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that its discovery portfolio company Quench Bio has emerged from stealth mode with the completion of a Series A financing. This follows a period of company creation, with seed investment and close involvement by Arix.

Finastra is investing further in Israel with a new office in Kfar Saba, just outside Tel Aviv. The office, which is home to over 330 employees, offers more space for the Finastra team to grow as the company strengthens its position in the country, and provides an ultra-modern workspace to inspire creativity and facilitate collaboration. The move will help the company support technological and financial innovation in the region, and drive adoption of its open development platform, FusionFabric.cloud.

Reiss Holdings Limited, the premium international fashion brand, today reported Christmas trading figures for 7 weeks to 18th January 2020.

Quench Bio, a company leveraging new insights into gasdermin biology and innate immunology to develop medicines for severe inflammatory diseases, today announced the completion of a $50 million Series A financing led by RA Capital Management ("RA Capital"), with participation from new Investor Abbvie Ventures. Atlas Venture ("Atlas") and Arix Bioscience plc ("Arix", LSE: ARIX) who co-founded and seeded the company, also participated in the Series A. Quench Bio has incubated at Atlas since inception.

Crowe Global (Crowe) reports an outstanding eight years of consecutive growth. The eighth largest audit, tax and advisory network in the world announced global revenues of US$4.4.bn in 2019, an increase of 3.5% (excluding Forex impact).

Bloc Ventures Limited (Bloc), the venture capital company focussed on early stage European deep technology investment, today announces it has raised over £20m in equity funding from UK industry leaders.